Ken-Ichi Hirano
Overview
Explore the profile of Ken-Ichi Hirano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
1523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamba T, Yanagawa M, Shimamura K, Yamaguchi S, Shirakura K, Okamura S, et al.
CJC Open
. 2025 Mar;
7(2):221-230.
PMID: 40060213
Approximately 2%-12% of individuals aged > 65 years worldwide are estimated to have an abdominal aortic aneurysm (AAA), with a mortality rate exceeding 60% in rupture cases. The sole preventive...
2.
Hirano K, Okamura S, Sugimura K, Miyauchi H, Nakano Y, Nochioka K, et al.
Nat Cardiovasc Res
. 2025 Feb;
PMID: 39948308
Heart disease is a major global threat. Triglyceride deposit cardiomyovasculopathy (TGCV) is an emerging, noncommunicable, adult-onset heart disease, first identified in Japanese patients with heart failure (HF) requiring cardiac transplantation....
3.
Nagasawa Y, Okamura S, Nishimura Y, Yamada T, Miyauchi H, Nakano Y, et al.
Clin Exp Nephrol
. 2025 Jan;
PMID: 39809936
Triglyceride deposit cardiomyovasculopathy (TGCV) is a rare cardiovascular disorder caused by defective intracellular lipolysis of triglyceride, resulting in heart failure and diffuse narrowing atherosclerosis. Recently, the registry of TGCV patients...
4.
Hirano K, Kodama K, Miyauchi H, Nagasawa Y, Nakano Y, Matsunaga M, et al.
Ann Nucl Cardiol
. 2024 Dec;
10(1):38-42.
PMID: 39635328
Triglyceride deposit cardiomyovasculopathy (TGCV) is an emerging rare heart disease with high mortality, characterized by defective intracellular lipolysis of triglycerides (TG). We developed diagnostic criteria for TGCV, in which low...
5.
Yamamoto H, Ikeda Y, Satomi K, Hirano K
CJC Open
. 2024 Nov;
6(9):1116-1120.
PMID: 39525815
No abstract available.
6.
Hirano K, Miyauchi H, Nakano Y, Kawaguchi Y, Okamura S, Nishimura Y, et al.
JACC Adv
. 2024 Jun;
2(4):100347.
PMID: 38938259
No abstract available.
7.
Ibrahim A, Fujimura T, Uno T, Terada T, Hirano K, Hosokawa H, et al.
Front Immunol
. 2024 May;
15:1365894.
PMID: 38779680
Background: Increased levels of plasminogen activator inhibitor-1 (PAI-1) in tumors have been found to correlate with poor clinical outcomes in patients with cancer. Although abundant data support the involvement of...
8.
Furuta Y, Osaki Y, Nakagawa Y, Han S, Araki M, Shikama A, et al.
J Atheroscler Thromb
. 2024 Mar;
31(9):1304-1318.
PMID: 38538338
Aim: This study aimed to analyze two cases of marked hypo-high-density lipoprotein (HDL) cholesterolemia to identify mutations in ATP-binding cassette transporter A1 (ABCA1) and elucidate the molecular mechanism by which...
9.
Ikeda Y, Shiba M, Yamamoto H, Itoh T, Okumura T, Nakano Y, et al.
ESC Heart Fail
. 2024 Feb;
11(2):1275-1278.
PMID: 38369807
No abstract available.
10.
Prevalence of triglyceride deposit cardiomyovasculopathy among patients with acute coronary syndrome
Nakano Y, Hirano K, Onishi T, Ando H, Amano T
Eur Heart J Acute Cardiovasc Care
. 2024 Jan;
13(3):293-295.
PMID: 38207089
No abstract available.